Reading view
Digital Twin based Automatic Reconfiguration of Robotic Systems in Smart Environments
Application and research progress of artificial intelligence in the diagnosis and treatment of rare lung diseases
Zhonghua Jie He He Hu Xi Za Zhi. 2026 Jan 12;49(1):78-83. doi: 10.3760/cma.j.cn112147-20250728-00445.
ABSTRACT
Rare lung diseases are a group of diseases characterized by significant clinical heterogeneity, challenging diagnosis and treatment processes, and diverse underlying causes. Due to their uncommon symptoms and limited awareness among healthcare providers, these diseases are frequently misdiagnosed or diagnosed too late, resulting in poor patient outcomes and placing a significant healthcare burden on the healthcare system. However, in recent years, the rapid advancements in artificial intelligence (AI) technology within the medical field have created new opportunities for early identification, accurate diagnosis, and personalized management of these diseases. A variety of AI techniques, ranging from traditional machine learning to more recent methods such as deep learning, reinforcement learning, and transfer learning, have been employed in areas such as clinical decision support, radiomics, omics data analysis, and the prediction of treatment responses for rare lung diseases. This article systematically reviews the latest research progress of AI applications in idiopathic pulmonary fibrosis, cystic fibrosis, idiopathic pulmonary arterial hypertension, and other rare lung diseases. It also emphasizes AI's potential benefits in disease classification, treatment evaluation, and prognosis prediction through illustrative research examples.
PMID:41483922 | DOI:10.3760/cma.j.cn112147-20250728-00445
Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models
World J Gastroenterol. 2025 Dec 14;31(46):111176. doi: 10.3748/wjg.v31.i46.111176.
ABSTRACT
Artificial intelligence (AI) is rapidly transforming the landscape of hepatology by enabling automated data interpretation, early disease detection, and individualized treatment strategies. Chronic liver diseases, including non-alcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma, often progress silently and pose diagnostic challenges due to reliance on invasive biopsies and operator-dependent imaging. This review explores the integration of AI across key domains such as big data analytics, deep learning-based image analysis, histopathological interpretation, biomarker discovery, and clinical prediction modeling. AI algorithms have demonstrated high accuracy in liver fibrosis staging, hepatocellular carcinoma detection, and non-alcoholic fatty liver disease risk stratification, while also enhancing survival prediction and treatment response assessment. For instance, convolutional neural networks trained on portal venous-phase computed tomography have achieved area under the curves up to 0.92 for significant fibrosis (F2-F4) and 0.89 for advanced fibrosis, with magnetic resonance imaging-based models reporting comparable performance. Advanced methodologies such as federated learning preserve patient privacy during cross-center model training, and explainable AI techniques promote transparency and clinician trust. Despite these advancements, clinical adoption remains limited by challenges including data heterogeneity, algorithmic bias, regulatory uncertainty, and lack of real-time integration into electronic health records. Looking forward, the convergence of multi-omics, imaging, and clinical data through interpretable and validated AI frameworks holds great promise for precision liver care. Continued efforts in model standardization, ethical oversight, and clinician-centered deployment will be essential to realize the full potential of AI in hepatopathy diagnosis and treatment.
PMID:41479639 | PMC:PMC12754151 | DOI:10.3748/wjg.v31.i46.111176
A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer
npj Digital Medicine, Published online: 31 December 2025; doi:10.1038/s41746-025-02260-3
A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancerOpinion: New medical technology presents hospitals with a prisoner’s dilemma
In 2026, Medtronic plans to launch a new robot to compete with a legacy market leader. This new robot is reportedly cheaper both in startup and sustained costs. That’s a welcome direction for any new medical technology, but it ignores a problem that hospitals, especially rural ones, face relating to technology and physician training.
Sometimes, rational decisions made in isolation lead to irrational outcomes for everyone involved. This is the lesson of the prisoner’s dilemma, a classic game theory puzzle demonstrating how cooperation and self-interest often clash. In the puzzle, two prisoners are each offered a deal: Inform on the other and go free, or stay silent and face a lighter sentence together. Fearing betrayal, both inform and both lose.


© PASCAL POCHARD-CASABIANCA/AFP via Getty Images
STAT+: Who will pay for AI in health care? 3 trends to watch in 2026
The health care industry is gearing up for a battle over whether and how clinical artificial intelligence should get paid for.
As of the end of September, the Food and Drug Administration has authorized 1,357 AI-enabled medical devices. But very few of those tools are actively paid for by insurers.
Some health policy experts and clinicians don’t see that as a problem.
Continue to STAT+ to read the full story…


© Christine Kao/STAT
In 2026, AI will move from hype to pragmatism
OpenAI bets big on audio as Silicon Valley declares war on screens
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial
Nature Medicine, Published online: 02 January 2026; doi:10.1038/s41591-025-04043-5
Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.How to reduce the environmental impact of wearable health-care devices
Nature, Published online: 31 December 2025; doi:10.1038/d41586-025-03982-w
A model quantifies the environmental footprint of wearable health-care electronics and identifies strategies to reduce their environmental toll.Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular Carcinoma
Gut Liver. 2025 Dec 31. doi: 10.5009/gnl250268. Online ahead of print.
ABSTRACT
The global burden of hepatocellular carcinoma (HCC) has shifted from viral to nonviral etiologies. However, successful antiviral therapy does not fully eliminate the risk of HCC, underscoring the demand for more effective surveillance strategies. Current screening methods, such as semiannual ultrasonography and the measurement of α-fetoprotein levels, offer suboptimal sensitivity for early detection. A cost-effective, reliable surveillance approach remains an unmet need. The Barcelona Clinic Liver Cancer staging system provides a framework to guide HCC therapy; yet, some gray zone exists, particularly for patients with intermediate-stage disease. Although tyrosine kinase inhibitors and immunotherapies have transformed the therapeutic landscape, their efficacies vary among patients, highlighting the necessity for personalized treatment strategies. In response to these challenges, artificial intelligence (AI) approaches have emerged as transformative tools in healthcare. By processing complex, nonlinear relationships and uncovering hidden patterns in clinical data, AI methods offer capabilities beyond those of traditional statistical methods. Furthermore, AI-driven multi-omics analysis holds promise for identifying novel biomarkers, thereby advancing precision medicine for HCC patients. This review introduces the potential of AI applications in enhancing the diagnosis, treatment, and prognosis of HCC.
PMID:41472345 | DOI:10.5009/gnl250268
Multi-Omics and Functional Analysis of BFSP1 as a Prognostic and Therapeutic Target in Liver Hepatocellular Carcinoma
Medicina (Kaunas). 2025 Dec 11;61(12):2196. doi: 10.3390/medicina61122196.
ABSTRACT
Background and Objectives: Although beaded filament structural protein 1 (BFSP1) may be involved in oncogenic mechanisms, its clinical relevance and functional role in liver hepatocellular carcinoma (LIHC) remain unclear. This study examined the prognostic significance, regulatory mechanisms, and potential therapeutic implications of BFSP1 in LIHC. Materials and Methods: Comprehensive bioinformatics analysis was performed across multiple platforms using datasets derived from The Cancer Genome Atlas. Differential gene expression, DNA methylation, copy number variation, immune cell infiltration, drug sensitivity, and co-expression networks were systematically examined. Functional enrichment analyses of protein-protein and gene-gene interaction networks were conducted using STRING and GeneMANIA. Additionally, short interfering RNA-mediated knockdown and wound-healing assays were performed in HepG2 cells to evaluate BFSP1 function in vitro. Results: The results showed that BFSP1 mRNA expression was significantly upregulated in tissues from LIHC patients. Elevated BFSP1 levels were associated with poorer prognostic patterns, which were further supported by detailed clinicopathological subgroup analyses. Furthermore, BFSP1 expression was correlated with promoter hypomethylation and associated with patterns of tumor-infiltrating immune cells, including specific immune cell subtypes such as M1 and M2 macrophages. Integrative analyses revealed strong associations between BFSP1 and drug sensitivity, as well as a regulatory network encompassing genes involved in the cell cycle, DNA repair, and metabolic processes. Functional knockdown of BFSP1 significantly reduced HepG2 cell migration in vitro, as assessed by wound healing assay, with decreased wound closure at 24 h (11.0% vs. 16.5%) and 48 h (7.4% vs. 12.5%) compared with the control (p < 0.05, n = 6 biological replicates). Conclusions: In conclusion, these findings suggest that BFSP1 functions as a multifaceted prognostic biomarker and a potential therapeutic target for LIHC.
PMID:41470198 | PMC:PMC12735119 | DOI:10.3390/medicina61122196
Artificial Intelligence Applications in the Diagnosis, Treatment, and Prognosis of Hepatocellular Carcinoma
Gut Liver. 2025 Dec 31. doi: 10.5009/gnl250268. Online ahead of print.
ABSTRACT
The global burden of hepatocellular carcinoma (HCC) has shifted from viral to nonviral etiologies. However, successful antiviral therapy does not fully eliminate the risk of HCC, underscoring the demand for more effective surveillance strategies. Current screening methods, such as semiannual ultrasonography and the measurement of α-fetoprotein levels, offer suboptimal sensitivity for early detection. A cost-effective, reliable surveillance approach remains an unmet need. The Barcelona Clinic Liver Cancer staging system provides a framework to guide HCC therapy; yet, some gray zone exists, particularly for patients with intermediate-stage disease. Although tyrosine kinase inhibitors and immunotherapies have transformed the therapeutic landscape, their efficacies vary among patients, highlighting the necessity for personalized treatment strategies. In response to these challenges, artificial intelligence (AI) approaches have emerged as transformative tools in healthcare. By processing complex, nonlinear relationships and uncovering hidden patterns in clinical data, AI methods offer capabilities beyond those of traditional statistical methods. Furthermore, AI-driven multi-omics analysis holds promise for identifying novel biomarkers, thereby advancing precision medicine for HCC patients. This review introduces the potential of AI applications in enhancing the diagnosis, treatment, and prognosis of HCC.
PMID:41472345 | DOI:10.5009/gnl250268
Multi-Omics and Functional Analysis of BFSP1 as a Prognostic and Therapeutic Target in Liver Hepatocellular Carcinoma
Medicina (Kaunas). 2025 Dec 11;61(12):2196. doi: 10.3390/medicina61122196.
ABSTRACT
Background and Objectives: Although beaded filament structural protein 1 (BFSP1) may be involved in oncogenic mechanisms, its clinical relevance and functional role in liver hepatocellular carcinoma (LIHC) remain unclear. This study examined the prognostic significance, regulatory mechanisms, and potential therapeutic implications of BFSP1 in LIHC. Materials and Methods: Comprehensive bioinformatics analysis was performed across multiple platforms using datasets derived from The Cancer Genome Atlas. Differential gene expression, DNA methylation, copy number variation, immune cell infiltration, drug sensitivity, and co-expression networks were systematically examined. Functional enrichment analyses of protein-protein and gene-gene interaction networks were conducted using STRING and GeneMANIA. Additionally, short interfering RNA-mediated knockdown and wound-healing assays were performed in HepG2 cells to evaluate BFSP1 function in vitro. Results: The results showed that BFSP1 mRNA expression was significantly upregulated in tissues from LIHC patients. Elevated BFSP1 levels were associated with poorer prognostic patterns, which were further supported by detailed clinicopathological subgroup analyses. Furthermore, BFSP1 expression was correlated with promoter hypomethylation and associated with patterns of tumor-infiltrating immune cells, including specific immune cell subtypes such as M1 and M2 macrophages. Integrative analyses revealed strong associations between BFSP1 and drug sensitivity, as well as a regulatory network encompassing genes involved in the cell cycle, DNA repair, and metabolic processes. Functional knockdown of BFSP1 significantly reduced HepG2 cell migration in vitro, as assessed by wound healing assay, with decreased wound closure at 24 h (11.0% vs. 16.5%) and 48 h (7.4% vs. 12.5%) compared with the control (p < 0.05, n = 6 biological replicates). Conclusions: In conclusion, these findings suggest that BFSP1 functions as a multifaceted prognostic biomarker and a potential therapeutic target for LIHC.
PMID:41470198 | PMC:PMC12735119 | DOI:10.3390/medicina61122196
Effectiveness of Digital Interventions for Low-Income, Food-Insecure Populations: Natural Language Processing Study of WIC Smartphone App User Reviews, 2013-2024
PIC-SURE: an open-source platform for integrating clinical and genomic data
npj Digital Medicine, Published online: 30 December 2025; doi:10.1038/s41746-025-02284-9
PIC-SURE: an open-source platform for integrating clinical and genomic data